case_images: PMC8724132_01
case_images: Fluoro-D-glucose PET/CT (FDG-PET/CT) images. (A,B) PET MIP (C) fused PET/CT, and (D) CT.
case_images: fmed-08-664520-g0001.jpg
case_images: PMC8724132_01_fmed-08-664520-g0001.jpg
case_images: F1
case_images: Endoscopic examination before (A) and after (B) tumor debulking.
case_images: fmed-08-664520-g0002.jpg
case_images: PMC8724132_01_fmed-08-664520-g0002.jpg
case_images: F2
case_images: Histopathology results. (A) hematoxylin-eosin-saffron, x20, (B) Ki-67 MIB1, x20, (C) pan-keratin AE1/AE3, x20, (D) epithelial membran antigen-EMA, x20, (E) smooth muscle actin, x20, and (F) vimentin, x20.
case_images: fmed-08-664520-g0003.jpg
case_images: PMC8724132_01_fmed-08-664520-g0003.jpg
case_images: F3
case_images: The histopathology analysis (Figure 3) of the resected tumor showed a biphasic tumor with small luminal ducts surrounded by myoepithelial abluminal cells (Figure 3A: hematoxylin-eosin-saffron, x20). The ki-67 immunohistochemistry proliferative index was about 50% (Figure 3B: MIB1, x20). The immunohistochemistry analysis showed the epithelial phenotype of luminal cells (Figure 3C: pan-keratin AE1/AE3, Figure 3D: epithelial membrane antigen-EMA, x20) and the myoepithelial phenotype of abluminal cells (Figure 3E: smooth muscle actin, Figure 3F: vimentin, x20).